Therapeutic areas
Therapeutic Solutions that Make a Difference
Discover our areas of medical specialization, where science meets innovation.
Stages
Cell Line Development
Preclinical
Clinical
In-Licensed
Regulatory Submission
Approved
Marketed
Mexico
Bone Health
Intra-Articular Hyaluronic Acid (1% Concentration)
Intra-Articular Hyaluronic Acid (1.5% Concentration)
Intra-Articular Hyaluronic Acid (2% Concentration)
PTH analog biosimilar
RANKL Inhibitor Biosimilar
Oncology
G-CSF biosimilar
Anti-VEGF biosimilar
RANKL Inhibitor Biosimilar
Cardiometabolic
GLP-1 receptor agonist (branded generic)
DPP-4 inhibitor + Biguanide
Immunology
Antiproliferative immunosuppressant
USA
Anti–IL-5R mAb biosimilar
Anti-sclerostin mAb biosimilar
PCSK9 mAb biosimilar
Mexico
Bone Health
Intra-Articular Hyaluronic Acid (1% Concentration)
Marketed
Intra-Articular Hyaluronic Acid (1.5% Concentration)
Marketed
Intra-Articular Hyaluronic Acid (2% Concentration)
Marketed
PTH analog biosimilar
Marketed
RANKL Inhibitor Biosimilar
In-Licensed
Oncology
G-CSF biosimilar
Regulatory Submission
Anti-VEGF biosimilar
Regulatory Submission
RANKL Inhibitor Biosimilar
In-Licensed
Cardiometabolic
GLP-1 receptor agonist (branded generic)
Regulatory Submission
DPP-4 inhibitor + Biguanide
Regulatory Submission
Immunology
Antiproliferative immunosuppressant
In-Licensed
USA
Anti–IL-5R mAb biosimilar
Cell Line Development
Anti-sclerostin mAb biosimilar
Cell Line Development
PCSK9 mAb biosimilar
Cell Line Development
Get in Touch
Tell us what you’re working on and what you’re looking for in a LATAM partner — together, we can build a partnership that opens doors for patients.
Accelerated partnership development.
Expansion into emerging markets.
Access to markets with untapped potential.
Short, mid and long-term opportunities.
Contact Us
Our team would love to hear from you
